Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer

被引：1
|
作者：
Prager, Gerald [1 ]
Argiles, Guillem [2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Vienna, Austria
[2] Vall d Hebron Univ Hosp, VHIO, Barcelona, Spain
来源：
ESMO OPEN | 2017年 / 2卷 / 03期
关键词：
RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; PLACEBO; TRIAL; COMBINATION;
D O I：
10.1136/esmoopen-2017-000205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [11] The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer
    Yoon, Sang Eun
    Hur, Joon Young
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    Kim, Seung Tae
    CANCER RESEARCH, 2019, 79 (13)
  • [12] Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
    Xu, Donghao
    Liu, Yu
    Tang, Wentao
    Xu, Lingsha
    Liu, Tianyu
    Jiang, Yudong
    Zhou, Shizhao
    Qin, Xiaorui
    Li, Jisheng
    Zhao, Jiemin
    Ye, Lechi
    Chang, Wenju
    Xu, Jianmin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [13] A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
    Xue, Wu-Song
    Men, Si-Ye
    Liu, Wei
    Liu, Reng-Hai
    MEDICINE, 2018, 97 (40)
  • [14] Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 62 - 62
  • [15] Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Narita, Yukiya
    Tsushima, Takahiro
    Ishihara, Makoto
    Todaka, Akiko
    Tanaka, Tsutomu
    Yokota, Tomoya
    Kadowaki, Shigenori
    Machida, Nozomu
    Ura, Takashi
    Fukutomi, Akira
    Ando, Masashi
    Onozawa, Yusuke
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Mori, Keita
    Yamazaki, Kentaro
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E15 - E22
  • [16] The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
    Yoon, Sang Eun
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    Kim, Seung Tae
    JOURNAL OF CANCER, 2019, 10 (07): : 1611 - 1615
  • [17] Treatment options after regorafenib failure in metastatic colorectal cancer
    Berretta, M.
    Fiorica, F.
    Quagliariello, V.
    Laterza, M. M.
    Facchini, G.
    Montopoli, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (13) : 4441 - 4442
  • [18] Treatment options after regorafenib failure in metastatic colorectal cancer
    Eraslan, E.
    Dogan, M.
    Yildiz, F.
    Ilhan, A.
    Oksuzoglu, O. B.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (09) : 3470 - 3477
  • [19] The efficacy and safety of sintilimab plus regorafenib in refractory metastatic colorectal cancer.
    Li, Rongrong
    Liu, Zhenyang
    Yin, Xianli
    Zeng, Deyu
    Jiang, Shaofeng
    Liu, Wu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15546 - E15546
  • [20] Regorafenib for metastatic colorectal cancer Reply
    Van Cutsem, Eric
    Grothey, Axel
    LANCET, 2013, 381 (9877): : 1538 - 1539
12345